Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

This publication has 9 references indexed in Scilit:

• RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
  International Journal of Antimicrobial Agents, 2020
• To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic
  Annals of the Rheumatic Diseases, 2020
• Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
  The Lancet, 2020
• Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
  The Lancet, 2020
• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
  The Lancet, 2020
• 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
  Annals of the Rheumatic Diseases, 2019
• A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
  Annals of the Rheumatic Diseases, 2017
• Effects of chloroquine on viral infections: an old drug against today's diseases
  The Lancet Infectious Diseases, 2003
• Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus
  Arthritis & Rheumatism, 1997